LanC Like Protein 2 - Pipeline Review, H2 2019
LanC Like Protein 2 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'LanC Like Protein 2 - Pipeline Review, H2 2019'; LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) pipeline Target constitutes close to 6 molecules.
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - LanC-like protein 2 is a protein encoded by the LANCL2 gene. It is important for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.
The report 'LanC Like Protein 2 - Pipeline Review, H2 2019' outlays comprehensive information on the LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 5 respectively. Report covers products from therapy areas Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Oncology which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Crohn's Disease (Regional Enteritis), Lupus Erythematosus, Multiple Sclerosis, Systemic Lupus Erythematosus and Ulcerative Colitis.
SCOPE
SUMMARY
According to the recently published report 'LanC Like Protein 2 - Pipeline Review, H2 2019'; LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) pipeline Target constitutes close to 6 molecules.
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - LanC-like protein 2 is a protein encoded by the LANCL2 gene. It is important for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.
The report 'LanC Like Protein 2 - Pipeline Review, H2 2019' outlays comprehensive information on the LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 5 respectively. Report covers products from therapy areas Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Oncology which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Crohn's Disease (Regional Enteritis), Lupus Erythematosus, Multiple Sclerosis, Systemic Lupus Erythematosus and Ulcerative Colitis.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
- The report reviews LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics and enlists all their major and minor projects
- The report assesses LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Companies Involved in Therapeutics Development
Landos Biopharma Inc
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles
BT-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-63 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-84 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NX-43 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2019: Landos Biopharma announces first patient dosed in global phase 2 trials of BT-11 in ulcerative colitis
May 15, 2019: Landos Biopharma announces publication of results from first-in-human phase 1 study of BT-11 in healthy volunteers
Mar 07, 2019: Landos Biopharma to present at upcoming investor conferences
Mar 05, 2019: Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11
Feb 21, 2019: Landos Biopharma announces publication supporting novel, dual mechanism of action for BT-11 in models of IBD
Jan 07, 2019: Landos Biopharma announces final safety results from phase 1 study of BT-11 in healthy volunteers
Jul 12, 2018: Landos doses first subject cohort in Phase l trial of BT-11 for IBD
Jun 05, 2018: Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018
May 01, 2018: Mechanistic and Human Translational Results for BT-11 in Models of IBD
Jun 05, 2014: European Patent issued advancing Biotherapeutics’ broad claims for treating and preventing Inflammation and Diabetes
May 19, 2014: BioTherapeutics awarded National Institutes of Health Small Business Innovation Research program award to advance novel therapy for IBD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Companies Involved in Therapeutics Development
Landos Biopharma Inc
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles
BT-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-63 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-84 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NX-43 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2019: Landos Biopharma announces first patient dosed in global phase 2 trials of BT-11 in ulcerative colitis
May 15, 2019: Landos Biopharma announces publication of results from first-in-human phase 1 study of BT-11 in healthy volunteers
Mar 07, 2019: Landos Biopharma to present at upcoming investor conferences
Mar 05, 2019: Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11
Feb 21, 2019: Landos Biopharma announces publication supporting novel, dual mechanism of action for BT-11 in models of IBD
Jan 07, 2019: Landos Biopharma announces final safety results from phase 1 study of BT-11 in healthy volunteers
Jul 12, 2018: Landos doses first subject cohort in Phase l trial of BT-11 for IBD
Jun 05, 2018: Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018
May 01, 2018: Mechanistic and Human Translational Results for BT-11 in Models of IBD
Jun 05, 2014: European Patent issued advancing Biotherapeutics’ broad claims for treating and preventing Inflammation and Diabetes
May 19, 2014: BioTherapeutics awarded National Institutes of Health Small Business Innovation Research program award to advance novel therapy for IBD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Landos Biopharma Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Landos Biopharma Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type,, H2 2019
COMPANIES MENTIONED
Landos Biopharma Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type,, H2 2019
COMPANIES MENTIONED
Landos Biopharma Inc
